Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Conditions
Interventions
Obeticholic Acid (OCA)
Placebo
Locations
59
United States
UC Davis Medical Center
Sacramento, California, United States
Scripps Clinic
San Diego, California, United States
University of Colorado, Denver
Aurora, Colorado, United States
University of Chicago
Chicago, Illinois, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Henry Ford Health System
Detroit, Michigan, United States
Start Date
January 1, 2012
Primary Completion Date
December 1, 2013
Completion Date
December 17, 2018
Last Updated
May 6, 2021
NCT04526665
NCT03301506
NCT03743272
NCT02846896
NCT03112681
NCT02963077
Lead Sponsor
Intercept Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions